SynBioBeta

Better vaccine delivery could mean better outcomes — and lower risk where it matters most 💉❤️🔬 📍SynBioBeta • May 4–7, 2026 • San Jose Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology

Paris-based biotech startup baCta has raised €7 million in Seed funding led by LocalGlobe and Daphni, with aims to scale its AI-driven bioproduction of astaxanthin, an antioxidant used in health and cosmetics. The company plans to leverage its proprietary yeast strain and advanced synthetic biology techniques to achieve competitive unit economics and enhance resilience in the supply chain for industrial ingredients. eu-startups.com/2026/03/paris-… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Generate Biomedicines has priced its shares at $16, successfully raising $400 million in its U.S. IPO, with 25 million shares sold. The company, known for its AI-driven drug discovery platform, focuses on developing protein-based therapies in immunology and oncology, including its lead candidate GB-0895 for severe asthma, currently in late-stage trials. Trading under the ticker "GENB" on Nasdaq begins Friday. reuters.com/business/healt… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

In a strategic move to enhance its oncology portfolio, Gilead Sciences has agreed to acquire Arcellx for an implied equity value of $7.8 billion, securing full ownership of the late-stage CAR T therapy anitocabtagene autoleucel (anito-cel). This acquisition consolidates Arcellx's innovative D-Domain platform with Gilead's established cell therapy infrastructure, positioning the company to accelerate development and commercialization efforts ahead of the therapy's FDA decision expected by December 2026. news.biobuzz.io/2026/02/23/bre… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Manus has expanded its partnership with the U.S. Department of Health and Human Services, receiving an additional $15 million to enhance domestic production of shikimic acid, a vital component for oseltamivir, the active ingredient in Tamiflu. This funding aims to strengthen U.S. health security by reducing reliance on foreign supply chains, addressing a critical vulnerability, as over 80% of essential medicine ingredients are sourced overseas. manusbio.com/articles/manus… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Turbine has raised $25 million in a Series B round led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and other existing investors. The funding will enhance Turbine's virtual cell platform and support a new partnership with a top 10 pharmaceutical company to model immune cell behavior, aiming to streamline the discovery of novel immunotherapy combinations. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

JOYN Foods , formerly Mush Foods, plans to triple revenues in 2026 and achieve EBITDA positivity by early 2027, leveraging its cost-effective mycelium-based meat blends to capture the price-sensitive foodservice market. With monthly sales exceeding $250k and partnerships with major suppliers like Sysco and US Foods, JOYN's 50CUT brand is gaining traction in K-12 cafeterias following recent approval from the South Carolina Purchasing Alliance. agfundernews.com/hybrid-meat-fo… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

French startup Verley has raised €32M ($37.6M) in Series A funding to scale production of its precision-fermented, cow-free whey proteins, targeting the U.S. market with initial product launches by the end of 2026. The oversubscribed round was led by Alven, with additional backing from Bpifrance and others, positioning Verley to meet increasing demand for high-protein alternatives amid a tightening supply of conventional whey. greenqueen.com.hk/verley-precisi… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

A universal antivenom sounds ambitious — which is exactly why it is worth paying attention to 🐍🧪🌍 📍SynBioBeta • May 4–7, 2026 • San Jose Register and join the conversation at SynBioBeta Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology

@Ginkgo Bioworks and @Invaio_Sciences have partnered to develop a microorganism capable of manufacturing peptide-based agricultural products, addressing the need for effective pest control as conventional methods become less viable. This collaboration leverages Ginkgo's advanced microbial strains and fermentation technology to optimize production processes, supporting Invaio's goal of delivering affordable and efficient crop protection solutions. prnewswire.com/news-releases/… Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

Only a small fraction goes toward proactive health — and that gap may be one of healthcare’s biggest opportunities 🏥📊🔬 📍SynBioBeta • May 4–7, 2026 • San Jose Register and join the conversation at SynBioBeta syntheticbiologysummit.com/?utm_source=x&… #SynBioBeta #Biomanufacturing #Engineering #StartupLife #SyntheticBiology